Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

July 23, 2023Open Access

Pitavastatin to Prevent Cardiovascular Disease in HIV Infection

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Participants with HIV infection who received pitavastatin had a lower risk of a major adverse cardiovascular event than those who received placebo over a median follow-up of 5.1 years. (Funded by the National Institutes of Health and others; REPRIEVE ClinicalTrials.gov number, NCT02344290.).

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Grinspoon et al. (Sun,) studied this question.

synapsesocial.com/papers/69435da70bf1812605412f82 https://doi.org/https://doi.org/10.1056/nejmoa2304146

Pitavastatin to Prevent Cardiovascular Disease in HIV Infection | Synapse

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1CORONARY ARTERY DISEASE IN LOW- TO INTERMEDIATE-RISK ASYMPTOMATIC PEOPLE WITH HIV: COMPARISON TO ASYMPTOMATIC COMMUNITY AND STABLE CHEST PAIN POPULATIONS WITHOUT KNOWN HIV2023 · 1 citations
2A Systematic Review of the Inclusion (or Exclusion) of Women in HIV Research2015 · 205 citations
3Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein2008 · 6,648 citations
4Conceptualizing the Risks of Coronary Heart Disease and Heart Failure Among People Aging with HIV: Sex-Specific Considerations2019 · 21 citations
5Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial2017 · 86 citations